Chevallier P - Search Results

1

Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience.

Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, Moreau P, Mechinaud F, Milpied N, Mohty M. Malard F, et al. Among authors: chevallier p. Biol Blood Marrow Transplant. 2014 Aug;20(8):1217-23. doi: 10.1016/j.bbmt.2014.04.021. Epub 2014 Apr 23. Biol Blood Marrow Transplant. 2014. PMID: 24769328 Free article.

2

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia.

Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahé B, Hamidou M, Maisonneuve H, Moreau P, Jardel H, Harousseau JL, Bataille R, Garand R. Chevallier P, et al. Br J Haematol. 2002 Jan;116(1):142-50. doi: 10.1046/j.0007-1048.2001.3205.x. Br J Haematol. 2002. PMID: 11841407 Free article.

3

Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.

Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M. Spisek R, et al. Among authors: chevallier p. Cancer Res. 2002 May 15;62(10):2861-8. Cancer Res. 2002. PMID: 12019165

4

Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients.

Chevallier P, Robillard N, Wuilleme-Toumi S, Méchinaud F, Harousseau JL, Avet-Loiseau H. Chevallier P, et al. Haematologica. 2004 Nov;89(11):1399-401. Haematologica. 2004. PMID: 15531467

5

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

Vigouroux S, Morin O, Moreau P, Méchinaud F, Morineau N, Mahé B, Chevallier P, Guillaume T, Dubruille V, Harousseau JL, Milpied N. Vigouroux S, et al. Among authors: chevallier p. Clin Infect Dis. 2005 Feb 15;40(4):e35-7. doi: 10.1086/427752. Epub 2005 Jan 25. Clin Infect Dis. 2005. PMID: 15712069

6

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726

7

Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.

Chevallier P, Touzeau C, Ayari S, Guillaume T, Harousseau JL, Delaunay J. Chevallier P, et al. Leuk Res. 2008 Aug;32(8):1321-2. doi: 10.1016/j.leukres.2007.09.009. Epub 2007 Oct 29. Leuk Res. 2008. PMID: 18029013

8

Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.

Royer PJ, Bougras G, Ebstein F, Leveque L, Tanguy-Royer S, Simon T, Juge-Morineau N, Chevallier P, Harousseau JL, Gregoire M. Royer PJ, et al. Among authors: chevallier p. Exp Hematol. 2008 Mar;36(3):329-39. doi: 10.1016/j.exphem.2007.11.001. Epub 2008 Jan 22. Exp Hematol. 2008. PMID: 18207305 Free article.

9

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, Bordigoni P, Vernant JP, Hunault M, Vigouroux S, Blaise D, Tabrizi R, Buzyn A, Socie G, Michallet M, Volteau C, Harousseau JL. Chevallier P, et al. J Clin Oncol. 2008 Oct 20;26(30):4940-3. doi: 10.1200/JCO.2007.15.6315. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606981

10

Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.

Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J. Chevallier P, et al. Int J Hematol. 2008 Sep;88(2):209-211. doi: 10.1007/s12185-008-0123-2. Epub 2008 Aug 1. Int J Hematol. 2008. PMID: 18668307

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

908 results

Search Page

Filters